Kodiak Sciences - Novel medicines for retinal disease
Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Kodiak aims to prevent and treat the leading causes of blindness in the developed world.
Our Company - Kodiak Sciences
New enhanced formulations for tarcocimab and KSI-501: designed to deliver strong immediacy and Kodiak’s signature 6-month durability • New phase 3 GLOW2 study enrolling patients in diabetic retinopathy: repeats successful GLOW1 study design with all patients on 6-month dosing •
Kodiak Sciences Inc (KOD): A Promising Bet in the …
Dec 9, 2024 · In the bustling arena of biopharmaceutical advancements, Kodiak Sciences Inc. (NASDAQ:KOD) is emerging as a key player, particularly in the field of retinal diseases. The company recently enjoyed a substantial 26.16% surge in its stock price, reaching $9.88, following a notable upgrade from Jefferies from “Hold” to “Buy.”
Our Pipeline - Kodiak Sciences
Our pipeline is designed to address key limitations of today’s therapies across a broad spectrum of retinal diseases. Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine.
Kodiak Sciences Announces Treatment of First Patients in Phase 3 …
PALO ALTO, Calif., May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...
Kodiak Sciences scraps development of eye drug, shares slump
Jul 24, 2023 · Kodiak Sciences will abandon further development of its lead drug to treat a type of eye disease after it failed in two late-stage studies, the company said on Monday, sending its shares...
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 · Kodiak announced this morning that it will “reboot” the program after a 5-mg dose of tarcocimab tedromer met the primary endpoint in one-year data from the GLOW trial in non-proliferative...
Kodiak Counts on Tarcocimab Eye Disease Program Despite …
Oct 10, 2024 · Kodiak is developing its lead investigational candidate, tarcocimab, a novel anti-VEGF antibody biopolymer conjugate, for the treatment of retinal vascular diseases. Such diseases include...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and …
May 2, 2024 · Novel small molecules and protein therapeutics highlight potential for targeted, high drug-antibody-ratio (DAR) conjugates built on Kodiak's ABC Platform.
Kodiak Sciences (KOD): A Pioneering Biotech Disrupting the …
Nov 19, 2024 · Kodiak Sciences Inc. (KOD) is a biopharmaceutical company at the forefront of developing transformative therapeutics to treat a broad spectrum of retinal diseases.